Norges Bank Invests $537.42 Million in Kenvue Inc. $KVUE

Norges Bank purchased a new position in Kenvue Inc. (NYSE:KVUE) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 25,676,929 shares of the company’s stock, valued at approximately $537,418,000. Norges Bank owned 1.34% of Kenvue as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Trust Co. of Vermont grew its stake in Kenvue by 266.8% during the second quarter. Trust Co. of Vermont now owns 1,581 shares of the company’s stock worth $33,000 after buying an additional 1,150 shares in the last quarter. Truvestments Capital LLC acquired a new stake in shares of Kenvue during the 1st quarter worth approximately $37,000. Clal Insurance Enterprises Holdings Ltd boosted its position in shares of Kenvue by 378.5% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company’s stock worth $39,000 after acquiring an additional 1,287 shares in the last quarter. First Pacific Financial bought a new position in Kenvue in the second quarter valued at approximately $54,000. Finally, Ransom Advisory Ltd acquired a new position in Kenvue during the first quarter valued at approximately $56,000. Institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on KVUE. Barclays raised their target price on Kenvue from $17.00 to $18.00 and gave the company an “equal weight” rating in a report on Monday, November 10th. Canaccord Genuity Group restated a “hold” rating and set a $15.00 price objective (down from $26.00) on shares of Kenvue in a research report on Wednesday, October 29th. Edward Jones lowered Kenvue from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 3rd. Evercore ISI set a $18.00 target price on Kenvue in a research note on Tuesday, October 28th. Finally, UBS Group dropped their target price on shares of Kenvue from $23.00 to $17.00 and set a “neutral” rating for the company in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and thirteen have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $20.23.

Kenvue Price Performance

Shares of KVUE opened at $17.31 on Friday. The company has a quick ratio of 0.69, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. The stock has a market cap of $33.15 billion, a PE ratio of 23.07 and a beta of 0.71. Kenvue Inc. has a 12-month low of $14.02 and a 12-month high of $25.17. The business has a 50-day simple moving average of $16.06 and a two-hundred day simple moving average of $19.56.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Monday, November 3rd. The company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.The firm had revenue of $3.76 billion for the quarter, compared to analyst estimates of $3.83 billion. During the same period last year, the firm posted $0.28 earnings per share. The business’s revenue for the quarter was down 3.5% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, November 26th. Shareholders of record on Wednesday, November 12th were given a $0.2075 dividend. This represents a $0.83 annualized dividend and a yield of 4.8%. The ex-dividend date was Wednesday, November 12th. Kenvue’s dividend payout ratio is 110.67%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.